Poly-Ub-substrate-degradative activity of 26S proteasome is not impaired in the aging rat brain

PLoS One. 2013 May 7;8(5):e64042. doi: 10.1371/journal.pone.0064042. Print 2013.

Abstract

Proteostasis is critical for the maintenance of life. In neuronal cells an imbalance between protein synthesis and degradation is thought to be involved in the pathogenesis of neurodegenerative diseases during aging. Partly, this seems to be due to a decrease in the activity of the ubiquitin-proteasome system, wherein the 20S/26S proteasome complexes catalyse the proteolytic step. We have characterised 20S and 26S proteasomes from cerebrum, cerebellum and hippocampus of 3 weeks old (young) and 24 month old (aged) rats. Our data reveal that the absolute amount of the proteasome is not dfferent between both age groups. Within the majority of standard proteasomes in brain the minute amounts of immuno-subunits are slightly increased in aged rat brain. While this goes along with a decrease in the activities of 20S and 26S proteasomes to hydrolyse synthetic fluorogenic tripeptide substrates from young to aged rats, the capacity of 26S proteasomes for degradation of poly-Ub-model substrates and its activation by poly-Ub-substrates is not impaired or even slightly increased in brain of aged rats. We conclude that these alterations in proteasome properties are important for maintaining proteostasis in the brain during an uncomplicated aging process.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / metabolism*
  • Animals
  • Brain / metabolism*
  • Cerebellum / enzymology
  • Cerebrum / enzymology
  • Electrophoresis, Polyacrylamide Gel
  • Hippocampus / enzymology
  • Hydrolysis
  • Male
  • Polyubiquitin / metabolism*
  • Proteasome Endopeptidase Complex / metabolism*
  • Protein Subunits / metabolism
  • Proteolysis*
  • Rats
  • Rats, Sprague-Dawley
  • Substrate Specificity

Substances

  • Protein Subunits
  • Polyubiquitin
  • Proteasome Endopeptidase Complex
  • ATP dependent 26S protease

Grants and funding

C.G. was supported by a PhD studentship from the Sonnenfeld-Stiftung, Berlin. M.M. was supported by Berliner Krebsgesellschaft (KÖFF201102). P.-M.K. was supported by the excellence cluster NeuroCure and the Deutsche Forschunsgemeinschaft (SFB TRR 34). P.W.S. and T.P.N. were supported by the EU Network of Excellence ‘Role of ubiquitin and ubiquitin-like modifiers in cellular recognition (RUBICON)’ Project number LSHC-CT-2005-018683. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.